A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2

Inclusion Criteria:

   - Meets ICSD-3 criteria for IH or Narcolepsy Type 2 and not undergoing pharmacologic
   treatment for the condition

   - Usual nightly total sleep at least 6 hours as single major rest period without naps

   - Epworth Sleepiness Scale of 10 or greater

   - Males or females age 18 to 65 years

Exclusion Criteria:

   - Any disorder causing hypersomnia other than IH or Narcolepsy Type 2

   - Usual bedtime later than midnight

   - Seizure disorder or history of syncope, unexplained loss of consciousness or seizure
   in the past 3 years

   - Beck Depression Inventory score greater than 19

   - Beck Anxiety Inventory score greater than 15

   - Significant history of or current suicidal ideation or behavior

   - BMI less than 18 kg/m2 or greater than 39 kg/m2

   - Positive toxicology screen or breathalyzer test

   - Clinically significant abnormal findings on safety assessments

   - Any significant medical or psychiatric disease or any condition that would put the
   patient at risk by participating in the study